• Dimerix receives ¥400 million (~AU$4.2 million) milestone payment from FUSO for opening clinical sites in Japan
• FUSO agreement may deliver up to ~AU$1.4 billion in total upfront and milestone payments, plus royalties
• Dimerix continues to pursue licensing opportunities in other territories

Dimerix Limited, a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, has received the first development milestone payment of ¥400 million (~AU$4.2 million) from FUSO Pharmaceutical Industries Ltd, the exclusive licensee of DMX-200 for FSGS in Japan. Under the agreement, FUSO has been granted exclusive rights to commercialize DMX-200 for FSGS in Japan. Dimerix may become eligible to receive further potential success-based development and regulatory milestone payments of up to ¥3 billion (~AU$30.6 million) in further potential development milestones, up to ¥6.8 billion (~AU$69.4 million) in potential sales milestones, and tiered royalties from fifteen to twenty percent of DMX-200 net sales in Japan. The opening of clinical sites in Japan will aid the recruitment of the ACTION3 clinical trial, with approximately 20 patients to be recruited to support potential approval in Japan. Dimerix now has four high-quality partners across multiple territories, providing strong support for advancing and commercializing DMX-200 as a potential new treatment for FSGS. Collectively across all licenses, Dimerix may become eligible for up to ~AU$1.4 billion in total upfront payments and potential milestone payments, plus royalties on net sales. Dimerix continues to pursue licensing opportunities with potential partners in territories not already licensed, including China.

Under the FUSO agreement, Dimerix may become eligible to receive up to ¥3 billion (~AU$30.6 million) in further potential development milestones and up to ¥6.8 billion (~AU$69.4 million) in potential sales milestones, plus tiered royalties from fifteen to twenty percent of DMX-200 net sales in Japan.